Contact Us

Permax
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

Did side effects from Permax (Pergolide) include:





Date the above injury occurred:

If you had an echocardiogram, what was the result?

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Permax

Permax Side Effects Lawsuits | Side Effects: Heart Valve Damage, Leaky Valve, Cardiac Valvulopathy
CLICK HERE TO DOWNLOAD OUR PERMAX INFORMATION PACKAGE

Permax Side Effects Could Result In Heart Valve Damage Lawsuits

Permax | Lawsuits, Lawyers | Side Effects: Heart Valve Damage, Leaky Valve, Cardiac Valvulopathy

Permax Removed From the Market

On March 29, 2007, the FDA announced that Permax (generic: pergolide) is being pulled off the market. There are additional drugs in the same class that can be substituted, Dr. Robert Temple of the FDA's office of drug evaluation said at a briefing. To date, 14 patients have needed to have heart valves replaced, Temple said, adding he believes that is a miscalculation. He estimated that between 12,000 and 25,000 people currently using Permax. Dr. Temple said withdrawal was demanded after two recent studies, published in The New England Journal of Medicine, indicated high rates of valve leakage; up to 20% in patients prescribed Permax.

New Studies Link Permax to Serious Heart Ailments

On January 3, 2007 new studies came out linking Permax with heart valve damage. A study by Italian researchers found that approximately one-fourth of Parkinson's patients taking Permax had moderate to severe heart valve troubles. An additional study, by German doctors, established that users of Permax were five to seven times more likely to have leaky heart valves than those on other types of Parkinson's medications. Both studies can be found in the New England Journal of Medicine.

In the Italian study, Dr. Renzo Zanettini and others at the Instituti Clinici di Perfezionamento in Milan obtained echocardiogram images of the hearts of 155 patients taking various Parkinson's medications and a comparison group of 90 healthy people. Moderate to severe valve problems were seen in 23% of those on Permax. In the German study, Dr. Rene Schade and associates in Berlin and in Montreal used records from over 11,400 Parkinson's patients in the United Kingdom. The rate of newly diagnosed leaky valves was increased among Permax users.

Permax (Generic: pergolide) has been linked to serious heart damage. Cardiac valvulopathy involving one or more valves has resulted in some patients taking Permax. Permax is used to treat Parkinson's disease. The details of the heart valve damage were detailed in a report by doctors at the Mayo Clinic. While the evidence in the report is based only on three cases treated at the clinic, the doctors say their evidence is enough to recommend that anyone with heart problems not take Pergolide, which is sold as Permax and has been used since 1999 to treat the tremors and restless leg syndrome from which Parkinson's disease patients suffer. "Further study is needed to see if this condition is under-recognized or, conversely, so rare that it escapes attention, says Dr. Raul Espinosa, a cardiologist at the Mayo Clinic and one of the authors of the report. But he and his colleagues write in the report that Pergolide should be discontinued if valvular disease is detected and no other cause identified.

Eli Lilly, the maker of the drug, says that Permax has had a safe record since coming on the market, but that the company would consider adding information about this heart risk to the label. In the cases that were treated at the clinic, three older women aged 61, 72, and 74 had been taking various doses of Permax daily for between three and seven years to treat their Parkinson's symptoms. They were diagnosed with serious valve disease; two required valve replacement surgery. None of the three had a prior history of heart disease. The findings led doctors back to their surgical records to see if any other people who had had valve replacement in the previous year had also been taking Pergolide. They found one out of 17 patients who had been on the drug. At the same time, a third woman came to the Mayo Clinic with the same diagnosis of valve disease and with a history of taking Pergolide for her Parkinson's.

Dr. Abraham Lieberman, the medical director of the National Parkinson Foundation in Miami, was one of the doctors who studied Pergolide in the 1980s when it was developed. There is evidence of pulmonary fibrosis that is associated with Pergolide, he says, "but there's a 14-year history of people taking Permax, and why hasn't this showed up sooner?

Parkinson's disease is a progressive neurological disorder resulting from the degeneration of neurons in a region of the brain that controls movement. The degeneration creates a shortage of the brain-signaling chemical known as dopamine, causing the movement impairments that characterize the disease. In the United States, at least 500,000 people are believed to suffer from Parkinson's disease, and about 50,000 new cases are reported annually, according to the National Institute of Neurological Disorders and Stroke.

Legal Rights for users of Permax

If you or a loved one took Permax and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).



 

PermaxRSS Feed

FDA Announces Withdrawal of Parkinson’s Drug from Market

Mar 30, 2007 | NewsInferno.com
The U.S. Food and Drug Administration (FDA) announced this week that all pergolide products are being removed from the market due to serious safety concerns. Pergolide drugs, which are used in the treatment of Parkinson’s disease, have been connected with an increased risk of severe heart-valve damage. The products being withdrawn are Eli Lilly’s Permax (marketed by Valeant Pharmaceuticals) and its generic counterparts made by Par and Teva. Pergolide is a dopamine agonist and is...

Parkinson's drug pulled from market

Mar 29, 2007 | AP
A drug used by several thousand patients with Parkinson's disease is being pulled from the market because of reports of heart valve damage. The Food and Drug Administration said Thursday that pergolide, sold under the name Permax and also in generic versions, is being withdrawn at the agency's request. There are other drugs in the same class that can be substituted, Dr. Robert Temple of the FDA's office of drug evaluation said at a briefing. At least 14 patients have needed to have heart...

FDA Announces Voluntary Withdrawal of Pergolide Products

Mar 29, 2007 | www.fda.gov
The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson’s disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients’ heart valves. The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva. Pergolide is in a class of medications...

FDA Public Health Advisory Pergolide (marketed as Permax)

Mar 29, 2007 | www.fda.gov
The FDA is notifying you that the companies that manufacture and distribute pergolide have agreed to withdraw this drug from the market due to the potential for heart valve damage.  Two new studies showed that patients with Parkinson’s disease who were treated with pergolide had an increased chance of serious damage to their heart valves when compared to patients who did not receive the drug.  Pergolide is a member of a class of drugs known as dopamine agonists and is used with...

FDA pulls Parkinson's drug

Mar 29, 2007 | UPI
A drug used to treat Parkinson's disease was pulled from the U.S. market Thursday because of a risk of heart damage. Officials from the Food and Drug Administration said they asked the marketer of the drug, sold under the brand name Permax, to voluntarily stop sales because of new reports that it can damage heart valves and cause them to leak. They said the marketer, Valeant Pharmaceuticals International, had agreed to discontinue wholesale distribution. Permax is in a class of drugs...

More Permax News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo